Aspirin Prescription and Outcomes in Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS)

American Journal of Kidney Diseases

Volumn 50, Issue 4, 2007, Pages 602-611

  Éthier, Jean ^a   Bragg Gresham, Jennifer L ^b   Piera, Luis ^c   Akizawa, Tadao ^d   Asano, Yasushi ^e   Mason, Nancy ^f,g   Gillespie, Brenda W ^f   Young, Eric W ^f  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Koga Red Cross Hospital   (Japan)

^f UNIVERSITY OF MICHIGAN   (United States)

^g Nephrology Pharmacy Associates   (United States)

Author keywords

Antiplatelet therapy; aspirin prescribing patterns; cardiovascular morbidity and mortality; hemodialysis patients

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; AUSTRALIA; CEREBROVASCULAR DISEASE; CHILD; CLINICAL PRACTICE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEMODIALYSIS PATIENT; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; NEW ZEALAND; PRESCRIPTION; RISK FACTOR; STROKE;

EID: 34548863352     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.07.007     Document Type: Article

References (51)

1. US Renal Data System. USRDS 2003 Annual Data Report (2003), The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
2. Herzog C.A., Ma J.Z., and Collins A.J. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 339 (1998) 799-805
3. Townsend R.R. Cardiac mortality in chronic kidney disease: A clearer perspective. Ann Intern Med 137 (2002) 615-616
4. Antiplatelet Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
5. Eidelman R.S., Hebert P.R., Weisman S.E., and Hennekens G.H. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 163 (2003) 2006-2010
6. Sanmuganathan P.S., Ghahramani P., Jackson P.R., Wallis E.J., and Ramsay L.E. Aspirin for primary prevention of coronary heart disease: Safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 85 (2001) 265-271
7. Berger J.S., Roncaglioni M.C., Avanzini F., Pangrazzi I., Tognoni G., and Brown D.L. Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-analysis of randomized controlled trials. JAMA 295 (2006) 306-313
8. Ridker P.M., Cook N.R., Lee I.-M., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 (2005) 1293-1304
9. Zanchetti A., Hansson L., Dahlöf B., et al. Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. J Hypertens 20 (2002) 2301-2307
10. Levey A.S., Beto J.A., Coronado B.E., et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32 (1998) 853-906
11. Young E.W., Goodkin D.A., Mapes D.L., et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS): An international hemodialysis study. Kidney Int Suppl 74 (2000) S74-S81
12. Pisoni R.L., Gillespie B.W., Dickinson D.M., et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS): Design, data elements, and methodology. Am J Kidney Dis 44 suppl 2 (2004) S7-S15
13. SAS Technical Support: GLIMMIX: A SAS Macro for Fitting Generalized Linear Mixed Models Using Proc Mixed and the Output Delivery System (ODS). Available at: http://ftp.sas.com/techsup/download/stat/glmm800.html. Accessed August 30, 2004
14. SAS Institute: SAS/STAT User's Guide, version 8, vol 2. Cary, NC, SAS Institute, 1999, p 1452
15. Klein J.P., and Moeschberger M.L. Survival Analysis: Techniques for Censored and Truncated Data (1997), Springer, New York, NY 416-418
16. Wright R.S., Reeder G.S., Herzog C.A., et al. Acute myocardial infarction and renal dysfunction: A high-risk combination. Ann Intern Med 137 (2002) 563-570
17. Shlipak M.G., Heidenreich P.A., Noguchi H., Chertow G.M., Browner W.S., and McClellan M.B. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 137 (2002) 555-562
18. Stafford R.S. Aspirin use is low among United States outpatients with coronary artery disease. Circulation 101 (2000) 1097-1101
19. McCormick D., Gurwitz J.H., Lessard D., Yarzebski J., Gore J.M., and Goldberg R.J. Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: Missed opportunities for prevention?. Arch Intern Med 159 (1999) 561-567
20. Beaulieu M.D., Blais R., Jacques A., Battista R.N., Lebeau R., and Brophy J. Are patients suffering from stable angina receiving optimal medical treatment?. QJM 94 (2001) 301-308
21. Brown J.B., Delea T.E., Nichols G.A., Edelsberg J., Elmer P.J., and Oster G. Use of oral antithrombotic agents among health maintenance organization members with atherosclerotic cardiovascular disease. Arch Intern Med 162 (2002) 193-199
22. Campbell N.C., Thain J., Deans H.G., Ritchie L.D., and Rawles J.M. Secondary prevention in coronary heart disease: Baseline survey of provision in general practice. BMJ 316 (1998) 1430-1434
23. Tonelli M., Bohm C., Pandeya S., Gill J., Levin A., and Kiberd B.A. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis 37 (2001) 484-489
24. McCullough P.A., Sandberg K.R., Borzak S., Hudson M.P., Garg M., and Manley H.J. Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J 144 (2002) 226-232
25. Berger A.K., Duval S., and Krumholz H.M. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 42 (2003) 201-208
26. Conti C.R. Management of patients with acute myocardial infarction and end-stage renal disease. J Am Coll Cardiol 42 (2003) 209-210
27. American Diabetes Association. Aspirin therapy in diabetes (position statement). Diabetes Care 20 (1997) 1772-1773
28. American Diabetes Association. Aspirin therapy in diabetes (position statement). Diabetes Care 23 suppl 1 (2000) S61-S62
29. Reddan D.N. Therapy for cardiovascular disease in patients with chronic kidney disease: Appropriate caution or the absence of data. Am Heart J 144 (2002) 206-207
30. Livio M., Benigni A., Vigano G., Mecca G., and Remuzzi G. Moderate doses of aspirin and risk of bleeding in renal failure. Lancet 1 8478 (1986) 414-416
31. Kaufman J.S. Antithrombotic agents and the prevention of access thrombosis. Semin Dial 13 (2000) 40-46
32. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 268 (1992) 1292-1300
33. Weisman S.M., and Graham D.Y. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 162 (2002) 2197-2202
34. Sreedhara R., Himmelfarb J., Lazarus J.M., and Hakim R.M. Anti-platelet therapy in graft thrombosis: Results of a prospective, randomized, double-blind study. Kidney Int 45 (1994) 1477-1483
35. Saran R., Dykstra D.M., Wolfe R.A., Gillespie B., Held P.J., and Young E.W. Association between vascular access failure and the use of specific drugs: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 40 (2002) 1255-1263
36. Shahar E., Folsom A.R., Romm F.J., et al. Patterns of aspirin use in middle-aged adults: The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 131 (1996) 915-922
37. Andreucci V.E., Fissell R.B., Bragg-Gresham J.L., et al. Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients. Am J Kidney Dis 44 suppl 2 (2004) S61-S67
38. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
39. Saran R., Canaud B.J., Depner T.A., et al. Dose of dialysis: Key lessons from major observational studies and clinical trials. Am J Kidney Dis 44 suppl 2 (2004) S47-S53
40. Eknoyan G., Beck G.J., Cheung A.K., et al. The Hemodialysis (HEMO) Study Group: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347 (2002) 2010-2019
41. Pisoni R.L., Bragg-Gresham J.L., Young E.W., et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44 (2004) 94-111
42. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
43. Weigert A.L., and Schafer A.I. Uremic bleeding: Pathogenesis and therapy. Am J Med Sci 316 (1998) 94-104
44. Di Minno G., Martinez J., McKean M.L., De La Rosa J., Burke J.F., and Murphy S. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med 79 (1985) 552-559
45. Gaspari F., Vigano G., Orisio S., Bonati M., Livio M., and Remuzzi G. Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition. J Clin Invest 79 (1987) 1788-1797
46. Remuzzi G., Perico N., Zoja C., Corna D., Macconi D., and Vigano G. Role of endothelium-derived nitric oxide in the bleeding tendency of uremia. J Clin Invest 86 (1990) 1768-1771
47. Diaz-Ricart M., Etebanell E., Cases A., et al. Erythropoietin improves signaling through tyrosine phosphorylation in platelets from uremic patients. Thromb Haemost 82 (1999) 1312-1317
48. Zhou X.J., and Vaziri N.D. Defective calcium signalling in uraemic platelets and its amelioration with long-term erythropoietin therapy. Nephrol Dial Transplant 17 (2002) 992-997
49. Ikonomidis I., Andreotti F., Economou E., et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 100 (1999) 793-798
50. Ridker P.M., Cushman M., Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 973-979
51. Eikelboom J.W., Hirsh J., Weitz J.I., et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655